Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Jury Finds Enhertu Infringes Seagen Patent, Awards US$41.8 Million in Damages
April 12, 2022
- CEPI to Fund NEC’s AI-Based Coronavirus Vaccine Development
April 12, 2022
- Pertussis, Diphtheria, Tetanus, Polio, Hib Vaccine Filed in Japan: BIKEN/Mitsubishi
April 12, 2022
- Astellas, GSK, 2 Other Firms Log 10%-Plus Drop in Workforce: Jiho Poll
April 11, 2022
- CMS Decision De-Facto Denial of All Medicare Patient Access to Aduhelm: Biogen
April 11, 2022
- Kowa Appeals to Intellectual Property High Court in Livalo Damage Suit
April 8, 2022
- Novartis’ Japan Sales Inch Down to 320.5 Billion Yen, Revolade Rises to Best Seller
April 8, 2022
- Meiji Begins US/Canada PII Study of PDE4 Inhibitor for Plaque Psoriasis
April 8, 2022
- Japan Ethical Drug Sales Up 3.5% in February: Crecon
April 8, 2022
- Japan Pharma Sales Tick Up 2.9% in FY2021: Encise
April 8, 2022
- New Grad Hiring Down 4.4% in Spring 2022, Downtrend for Sales Reps Continues: Poll
April 7, 2022
- Jardiance Now Allowed for Use in HFpEF Patients: Label Update
April 7, 2022
- Detailing Activities via Webinars Chalk Up Double-Digit Growth in February: Intage
April 7, 2022
- Ratio of Blood-Based Gene Profiling Test at 1.4%; Cervical Cancer Most Frequently Tested: Survey
April 7, 2022
- Jardiance, Ofev Drive Up Boehringer’s Japan Sales in 2021
April 6, 2022
- Teijin, Iktos Ink Pact for AI-Based Discovery of Small Molecule Drugs
April 6, 2022
- Lundbeck Launches Japan-US PII for Multiple System Atrophy Treatment
April 6, 2022
- Pfizer Tops 2021 Global Pharma Ranking on Vaccine Boon: Jiho Tally
April 6, 2022
- Fujifilm Completes Acquisition of Atara’s US Cell Therapy Site
April 6, 2022
- Shionogi-Led Continuous Manufacturing JV Now Up and Running
April 4, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…